Entera Bio (ENTX) Total Liabilities (2017 - 2026)

Entera Bio (ENTX) has reported Total Liabilities for 10 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities rose 9.95% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 9.95% YoY) and the FY2025 annual result came in at $2.9 million, up 120.76% from the prior year.
• Total Liabilities fell to $2.4 million in Q1 2026 per ENTX's latest filing, from $2.9 million in the prior quarter.
• Over the last five years, Total Liabilities for ENTX reached as high as $2.9 million in Q4 2025 and fell as low as $1.2 million in Q3 2022.
• A 5-year average of $1.9 million and a median of $1.8 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities slumped 59.88% — and 2025, when it jumped 120.76%.
• Year by year, Total Liabilities stood at $1.4 million in 2022, then rose by 0.44% to $1.4 million in 2023, then decreased by 5.0% to $1.3 million in 2024, then soared by 120.76% to $2.9 million in 2025, then dropped by 15.56% to $2.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $2.4 million, $2.9 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.